Company Overview
Company Type: Private Company
Website: notchtx.com
Number of Employees: 75
Year Founded: 2018
Total Amount Raised (CAD mm)†: 107.83
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Notch Therapeutics (Canada) Inc. develops gene-edited allogeneic T-cell therapies from pluripotent stem cells for the treatment of cancer. It offers induced pluripotent stem cell AlloCAR therapy products for non-Hodgkin lymphoma, leukemia, and multiple myeloma. The company was incorporated in 2018 and is based in Vancouver, Canada with additional locations in Toronto, Canada; and Seattle, Washington.


Financial Information (Currency: CAD, in mm)
Total Revenue
 18.6
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 75
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Main, David J. 
President, CEO & Director
Zandstra, Peter 
Co-Founder, Senior Science & Technology Advisor and Member of Scientific Advisory Board
Zúñiga-Pflücker, Juan Carlos
Scientific Co-Founder & Co-Chairman of Scientific Advisory Board
Alam, Kamran 
EVP of Finance & CFO
Titus, Emily 
Senior Vice President of Technical Operations
Bond, Chris 
Chief Scientific Officer
Barthe, Cari 
Director of People & Culture
Leong, Connie 
Director & Corporate Controller

Key Board Members
Name
Title
Main, David J. 
President, CEO & Director
Zandstra, Peter 
Co-Founder, Senior Science & Technology Advisor and Member of Scientific Advisory Board
Zúñiga-Pflücker, Juan Carlos
Scientific Co-Founder & Co-Chairman of Scientific Advisory Board
Biggar, Stephen R.
Director
Chen, Yvonne Y.
Member of Scientific Advisory Board
Lee, Heather 
Director
Mikkola, Hanna 
Member of Scientific Advisory Board
Nielsen, Ulrik B.
Director
Rossant, Janet 
Director
Saha, Kris 
Member of Scientific Advisory Board
Stout, Caroline 
Director
Zweigerdt, Robert 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
500-887 Great Northern Way | Vancouver, BC | V5T 4T5 | Canada
Phone: 778-654-8588   Fax: 604-243-7624

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Amplitude Ventures
Feb-10-2021
Minority
-
Series A
-
Casdin Capital, LLC
Feb-10-2021
Minority
-
Series A
-
CCRM Enterprises Inc.
Feb-10-2021
Unknown
-
Series A
-
EcoR1 Capital, LLC
Feb-10-2021
Minority
-
Series A
-
Lumira Ventures
Feb-10-2021
Unknown
-
Series A
Benjamin Rovinski


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-10-2021
Feb-10-2021
Private Placement
Target
Notch Therapeutics (Canada) Inc.
Allogene Therapeutics, Inc. (NasdaqGS:ALLO),Lumira Ventures,EcoR1 Capital, LLC,Casdin Capital, LLC,Samsara BioCapital LLC,Amplitude Ventures,CCRM Enterprises Inc.

85.00
Nov-05-2019
Nov-05-2019
Merger/Acquisition
Target
Notch Therapeutics (Canada) Inc.
Allogene Therapeutics, Inc. (NasdaqGS:ALLO)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-13-2023
Company Conference Presentations
Notch Therapeutics Inc. Presents at Mass General Brigham World Medical Innovation Forum 2023, Jun-13-2023 03:35 PM
Apr-12-2023
Company Conference Presentations
Notch Therapeutics Inc. Presents at The Cell & Gene Meeting on the Mediterranean, Apr-12-2023 02:30 PM
Feb-07-2023
Company Conference Presentations
Notch Therapeutics Inc. Presents at The 9th Annual Immuno-Oncology 360 Summit, Feb-07-2023 03:25 PM
Feb-07-2023
Company Conference Presentations
Notch Therapeutics Inc. Presents at IO Cell Therapy 360°, Feb-07-2023
Nov-08-2022
Executive/Board Changes - Other
Notch Therapeutics Inc. Announce Executive Appointment


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 22, 2023 06:24 AM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc
Reports
52
GlobalData

Sep 15, 2023 04:18 AM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
21
GlobalData

Jun 22, 2023 02:07 AM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc
Reports
44
GlobalData

Jun 09, 2023 05:31 AM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
20
GlobalData

Mar 15, 2023 03:09 AM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc
Reports
43
GlobalData

Mar 10, 2023 03:48 AM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Dec 14, 2022 07:34 PM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc
Reports
42
GlobalData

Dec 09, 2022 12:49 AM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
18
GlobalData

Sep 16, 2022 09:30 PM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc
Reports
41
GlobalData

Sep 15, 2022 04:26 AM
Notch Therapeutics (Canada) Inc.
Notch Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Main, David J. 
President, CEO & Director
778-654-8588
604-243-7624

Zandstra, Peter 
Co-Founder, Senior Science & Technology Advisor and Member of Scientific Advisory Board
778-654-8588
604-243-7624

Zúñiga-Pflücker, Juan Carlos
Scientific Co-Founder & Co-Chairman of Scientific Advisory Board
778-654-8588
604-243-7624

Biggar, Stephen R.
Director
778-654-8588
604-243-7624

Chen, Yvonne Y.
Member of Scientific Advisory Board
778-654-8588
604-243-7624

Lee, Heather 
Director
778-654-8588
604-243-7624

Mikkola, Hanna 
Member of Scientific Advisory Board
778-654-8588
604-243-7624

Nielsen, Ulrik B.
Director
778-654-8588
604-243-7624

Rossant, Janet 
Director
778-654-8588
604-243-7624

Saha, Kris 
Member of Scientific Advisory Board
778-654-8588
604-243-7624

Stout, Caroline 
Director
778-654-8588
604-243-7624

Zweigerdt, Robert 
Member of Scientific Advisory Board
778-654-8588
604-243-7624

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Main, David J. 
President, CEO & Director
778-654-8588
604-243-7624

Zandstra, Peter 
Co-Founder, Senior Science & Technology Advisor and Member of Scientific Advisory Board
778-654-8588
604-243-7624

Zúñiga-Pflücker, Juan Carlos
Scientific Co-Founder & Co-Chairman of Scientific Advisory Board
778-654-8588
604-243-7624

Alam, Kamran 
EVP of Finance & CFO
778-654-8588
604-243-7624

Titus, Emily 
Senior Vice President of Technical Operations
778-654-8588
604-243-7624

Bond, Chris 
Chief Scientific Officer
778-654-8588
604-243-7624

Barthe, Cari 
Director of People & Culture
778-654-8588
604-243-7624

Leong, Connie 
Director & Corporate Controller
778-654-8588
604-243-7624

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
